PAA 2.63% 19.5¢ pharmaust limited

Ann: MND Trial Successfully Completes First Patient Cohort, page-157

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,855 Posts.
    lightbulb Created with Sketch. 2902
    Monepatel, why it has the upper hand. It is one of the unique molecules that passes through the BBB to treat neurodegenerative disorders. 100% of large molecules 98% small cannot. Not only Monepatel passes BBB we know it’s safety and tolerability due to prior approval. @IndexInvestor might find this interesting.

    Just need liquid formulation (if same PK/PD as tablet formulation) may be considered same drug by FDA.
    https://hotcopper.com.au/data/attachments/5933/5933250-b50fa8e98ab550dd1cbbd81845f0f450.jpg

 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.